Amniotic Epithelial Cells
Identification
- Name
- Amniotic Epithelial Cells
- Accession Number
- DB15868
- Description
Amniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus.1,2 These cells are potential candidates for allogeneic cell therapy and regenerative medicine due to their potential for differentiation and multiplication.1
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Cell transplant therapies
Other cell transplant therapies - Synonyms
- hAECs
- Human Amniotic Epithelial Cells
- External IDs
- Amniotic Epithelial Cells
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Amniotic epithelial cells have immunosuppression properties, the likely reason why these cells seem to be resistant to rejection after allotransplantation. Further therapeutic effects of these cells include reported neuroprotection and neuroregeneration properties, attributed to the growth factor secretion by AECs. These cells are being investigated as a therapy against many different conditions, some of which include lung fibrosis, liver fibrosis, multiple sclerosis, congenital metabolic disorders, familial hypercholesterolemia, spinal cord injuries, ophthalmic diseases, and Parkinson’s disease.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Yang PJ, Yuan WX, Liu J, Li JY, Tan B, Qiu C, Zhu XL, Qiu C, Lai DM, Guo LH, Yu LY: Biological characterization of human amniotic epithelial cells in a serum-free system and their safety evaluation. Acta Pharmacol Sin. 2018 Aug;39(8):1305-1316. doi: 10.1038/aps.2018.22. Epub 2018 Mar 22. [PubMed:29565036]
- Atala A., Lanza R., Mikos T., and Nerem R. (2019). Principles of Regenerative Medicine (3rd ed.). Elsevier. [ISBN:9780128098936]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Not Yet Recruiting Treatment Asherman's Syndrome 1 1 Recruiting Treatment Infertility / Premature Ovarian Failure (POF) / Primary Ovarian Insufficiency 1 1 Unknown Status Treatment HTLV-1 Associated Myelopathy 1 1 Unknown Status Treatment Spastic Cerebral Palsy 1 1, 2 Not Yet Recruiting Treatment Nonunion Fractures 1 0 Not Yet Recruiting Treatment Intrauterine Adhesions 1 Not Available Recruiting Prevention Acute-graft-versus-host Disease / Graft Versus Host Disease, Acute 1 Not Available Unknown Status Treatment Premature Ovarian Failure (POF) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on September 21, 2020 09:44 / Updated on September 22, 2020 07:00
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})